9.65
+0.29(+3.10%)
Currency In USD
Address
9804 Medical Center Drive
Rockville, MD 20850
United States of America
Phone
240 552 8181
Website
Sector
Healthcare
Industry
Biotechnology
Employees
353
First IPO Date
September 17, 2015
| Name | Title | Pay | Year Born |
| Mr. Curran M. Simpson M.S. | President, Chief Executive Officer & Director | 881,250 | 1962 |
| Mr. Mitchell Chan M.B.A. | Executive Vice President & Chief Financial Officer | 205,311 | 1981 |
| Mr. Patrick J. Christmas II, J.D. | Executive Vice President & Chief Strategy and Legal Officer | 723,558 | 1971 |
| Dr. Stephen Pakola M.D. | Executive Vice President & Chief Medical Officer | 750,334 | 1969 |
| Dr. Olivier Danos Ph.D. | Executive Vice President & Chief Scientific Officer | 770,124 | 1958 |
| Dr. Ram Palanki Pharm.D. | Executive Vice President of Commercial Strategy & Operations | 0 | 1976 |
| Ms. Shiva G. Fritsch | Chief Communications & People Officer | 0 | N/A |
| Craig Malzahn | Executive Vice President, Product Development & Chief Technology Officer | 0 | N/A |
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.